Introduction
Statins are used worldwide for the treatment of hyperlipidemia, and their main therapeutic action is to reduce total and LDL cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase [1] [2] [3] [4] . In addition to the benefits of lowering cholesterol, statins have other beneficial effects, including improvement of endothelial function and reduc-nisms of simvastatin-induced myotoxicy have been reported to be associated with simvastatin-induced Ca 2 release from both ryanodine receptor (RyR) and mitochondria in human skeletal muscle fibers 15) . Type 1 RyR (RyR1) is distributed mainly in skeletal muscle, but has been reported to be also manifested in the THP-1 cell line and human B-lymphocytes 16, 17) . Thus, we theorized that statin-induced Ca 2 release could also be observed in human CD19 cells.
In this study, to test whether the alteration in Ca 2 homeostasis is related to statin-induced muscle damage, we examined rosuvastatin-induced Ca 2 release using flow cytometry in human CD19 primary B cells from healthy volunteers, patients with elevation of creatine kinase (CK), and patients without elevated CK during statin treatment.
Materials and Methods

Reagents
4-Chloro-m-cresol (4Cmc) was obtained from Calbiochem (San Diego, CA), and thapsigargin and ionomycin were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Fluo-3 acetoxymethyl ester was obtained from Molecular Probes (Eugene, OR), xestospongin C from BIOMOL International LP (Plymouth Meeting, PA), and cerivastatin from Toronto Research Chemicals (Ontario, Canada). Simvastatin, fluvastatin, rosuvastatin, and pravastatin were a gift from Daiichi-Sankyo Co. Ltd (Tokyo, Japan).
Subjects
Blood samples were obtained from 8 rosuvastatin-using patients who had developed elevated CK levels (range: 282 − 2,193 IU/L), 16 rosuvastatin users with no elevation of CK levels (less than 200 IU/L), and 45 healthy adult volunteers. Mean age at the time of enrollment in the study was 57.4 years (range, 20 − 80), 53.1 years (range, 31 − 77), and 37.6 years (range, 24 − 75), respectively. None of the patients were taking fibrates with statin, and myoglobinuria was not observed. Gifu University Hospital Ethics Committee approved the study protocol, and all patients gave informed consent. Serum CK level was measured using a Quick Auto Neo CK Kit (Shino-Test Co., Tokyo, Japan).
Human Peripheral Blood Mononuclear Cells (PBMCs) and THP-1 Cell Line
PBMCs were isolated using Ficoll-Hypaque density gradient centrifugation. The THP-1 cell line was obtained from the Health Science Research Resources Bank (Osaka, Japan). and routinely cultivated in RPMI 1640 (Sigma-Aldrich Chemical Co., St. Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (ICN Biomedical Inc., Aurora, OH) and 100 U/mL penicillin-streptomycin (Gibco BRL, Life Technologies Inc., Rockville, MD), and maintained at 37 in a humidified atmosphere of 95% air and 5% CO2, as described previously 16, 18) .
Measurement of Intracellular Calcium
Relative changes in intracellular calcium ([Ca 2 ]i) in B cells were derived from changes in the fluorescence intensity of fluo-3-loaded cells 17, 19) . PBMCs (2 10 6 /mL) were loaded with 1 M acetoxy-methyl ester of fluo-3 by incubation in subdued light (30 min, 25 ) . For dose-response experiments, changes in [Ca 2 ]i were examined after addition of each statin at the indicated concentrations.
Rosuvastatin, simvastatin, fluvastatin, cerivastatin, and pravastatin were dissolved in 98% N.N-Dimethyl formamide, 99.5% ethanol, 99.7% methanol, Mg 2 -/ Ca 2 -free PBS, and Mg 2 -/Ca 2 -free PBS, respectively, according to the attached industrial information for each drug. The respective solvents were used as controls and showed no changes in [Ca 2 ]i (data not shown). All measurements were performed in triplicate.
Statistical Analysis
Data are expressed as the mean SE. The MannWhitney U-test was used to compare data between groups, and statistical significance was reached when p 0.05.
Results
Effect of Statins on Ca 2 Release in THP-1 Cell Line and CD19 Primary B Cells
The dose-dependent effects of rosuvastatin, simvastatin, fluvastatin, cerivastatin, and pravastatin on 
Statin-Induced Ca 2 Release from RyR-Sensitive Pool and Mitochondrial Compartment in THP-1 Cell Line
The THP-1 cell line was used to characterize the mechanism of statin-induced increases in [Ca 2 ]i because sufficient CD19 cells were not easily prepared for the study. For this characterization, we used simvastatin because it does not contain calcium in the formulation while rosuvastatin does contain calcium by the formation of a water-insoluble complex with EGTA solution.
To determine whether simvastatin-induced Ca 2 release occurred through a RyR1 channel, we used xestospongin C, a selective inhibitor of IP3 receptor, and 4Cmc, a selective RyR-stimulating agent. In the presence of 1 mM EGTA and 1 M xestospongin C, 100 M simvastatin induced robust Ca 2 release. No further release was observed by 1 mM 4Cmc treatment and by subsequent application of 1 M ionomycin ( Fig. 2A) .
This result suggested that simvastatin depleted not only RyR-sensitive endoplasmic reticulum (ER) stores but also mitochondrial stores. Consistent with is finding, simvastatin was capable of increasing [Ca 2 ]i after Ca 2 release was induced by 4Cmc. To further clarify the effect of simvastatin on mitochondrial store, we tested its ability to increase [Ca 2 ]i after application of 100 nM thapsigargin. In the presence of 1 mM EGTA, after depletion of Ca (Fig. 2B) . These results strongly suggested that simvastatin-induced Ca 2 release was derived from both RyR-sensitive ER and mitochondrial stores. (Fig. 3A) . Additionally, Ca 2 release was compared between pre-and post-treatment for at least three months in rosuvastatin-using patients without CK elevation (n 3). There was no significant differ- (Fig. 3B) .
Rosuvastatin-Induced
We demonstrated Ca 2 release in CD19 primary B cells from rosuvastatin-using patients with elevatied CK (n 8) ( Table 1 ) and compared them with patients who showed no CK elevation (n 16). As 
Discussion
LDL cholesterol has been incriminated as a causative factor in ischemic heart disease and cerebral vascular disturbance by many epidemiological surveys. Statins, which inhibit HMG-CoA reductase and effect improvements in serum lipid levels, are used worldwide [1] [2] [3] [4] ; however, serious side effects of muscle toxicity, such as myopathy and rhabdomyolysis, have been reported. The pathogenic mechanisms of rhabdomyolysis have not yet been elucidated although they have been researched from various aspects; however, it has been reported that statin-induced apoptosis is related to molecular mechanisms for muscle damage [21] [22] [23] [24] [25] . Because elevation of serum CK levels caused by statin use has been reported in malignant hyperthermia (MH)-susceptible patients 26, 27) , it is possible that rhabdomyolysis triggered by statins involves a mechanism similar to that of MH. MH is a pharmacogenetic disorder of skeletal muscle triggered by volatile anesthetics and depolarizing muscle relaxants [28] [29] [30] [31] . The majority of MH is caused by rare mutations of the RyR1 gene 32, 33) . In fact, RyR1-mediated Ca 2 release by 4Cmc was increased in pig lymphocytes in a study of an MH swine model 34) . Further, more convincing evidence for the involvement of RyR and mitochondria in statin-mediated changes in [Ca 2 ]i has recently been demonstrated using human skeletal muscle fibers 15) . Since the localization of RyR has recently been found in mitochondrial membranes 35) , statin-induced Ca 2 release from mitochondria may be related to the RyR on mitochondrial membranes. In this study, we investigated Ca 2 release by statins using the THP-1 cell line and CD19 B primary lymphocytes since both express RyR1 16, 17) . Here we demonstrated that statin-induced Ca 2 release was derived from RyR-sensitive and mitochondria stores in the THP-1 cell line. Although rosuvastatin could not be used for the in vitro study due to its compound characteristics, our findings suggest that statins, at least simvastatin, induce Ca 2 release from ryanodinesensitive stores and mitochondria. We found little effect on Ca 2 release by pravastatin, but it is consistent with the results from a report using mouse skele- tal muscle fibers 36) . It is currently unknown whether pravastatin induces Ca 2 release in vivo differently from in vitro, or whether it causes Ca 2 -independent mechanisms, because there have been cases of rhabdomyolysis and CK elevation in pravastatin-using patients 37) . At present, it is also possible that each drug's affinities to the molecular targets that cause Ca 2 release vary in different tissues. Additionally, although rosuvastatin showed the most potent Ca 2 release among the statins tested, this may be due to Ca 2 -induced Ca 2 release caused by calcium salt in the formula.
The results for rosuvastatin-induced Ca 2 release in CD19 primary B cells from healthy subjects and rosuvastatin-users provided important insights regarding the pathogenesis of statin-induced myopathy as well as the development of diagnostic methods. We found the flow cytometric measurement of Ca 2 release using two concentrations (30 and The graph indicates the peak % fluo-3 cells (mean S.E.) after 30 and 80 M rosuvastatin for rosuvastatin users who showed no CK elevation (n 16) and rosuvastatin-using patients who indicated CK elevation (n 8). There were significant differences in peak % fluo-3 cells between groups at 30 M (p 0.011) and 80 M (p 0.0008).
reflects muscle damage, but the damage degree may also be influenced by statin-susceptible genes 38) . If the sensitivity and specificity of the test can be thoroughly established, this laboratory test for Ca 2 release using CD19 primary B lymphocytes may be useful to identify individuals who are susceptible to statininduced muscle damage, at least for rosuvastatin, prior to statin use.
More recently, a genome-wide study for statininduced myopathy showed that an increased risk of statin-induced myopathy was significantly associated with common variants of the SLCO1B1 gene, which encodes the organic anion-transporting polypeptide OATP1B1 39) . Since the OATP1B1 has been reported to regulate the hepatic uptake of statins 40, 41) , the SLCO1B1 gene is likely to the contribute to increased risk of myopathy through its effect on blood and tissue levels of statins. Although it is unknown how our data relate to SLCO1B1 gene variants at present, the results from this elegant genome-wide study give important insights into the pathogenesis of this complex pharmacogenetic disease and also the risk genes. If abnormal increases in myoplasmic Ca 2 are responsible for triggering myopathy, dose-dependent effects of statins on Ca 2 levels in our study suggest possible interactions between the SLCOB1 genes and statins' molecular targets that are responsible for increasing Ca 2 levels. One such molecular target may be the RyR1 gene, but this gene was apparently difficult to associate with the disease in the genome-wide study because of the rarlty of its variants. Considering these difficulties in finding rare risk variants, testing statininduced Ca 2 responses may be useful to complement SLCO1B1 genotyping in order to identify susceptible individuals.
